Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups

American Journal of Cardiology

Volumn 91, Issue 5 SUPPL. 1, 2003, Pages 3-10

  Blasetto, James W ^a   Stein, Evan A ^b,c   Brown, W Virgil ^d   Chitra, Rohini ^a   Raza, Ali ^a   McKenney, James M ^e  

^a ASTRAZENECA   (United Kingdom)

^b Metabolic and Atherosclerosis Research Center   (United States)

^c Pharmaceutical Product Development   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLYCEROL BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0037422116     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00003-1     Document Type: Conference Paper

References (25)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
2. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels . N Engl J Med. 335:1996;1001-1009.
3. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
5. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruger W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622.
6. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomised placebo-controlled trial . Lancet. 360:2002;7-22.
7. Ballantyne C.M. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol. 82:1998;3Q-12Q.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
9. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med. 341:1999;498-511.
10. Stein E.A., Lane M., Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 81:1998;66B-69B.
11. Pearson T.A., Laurora I., Chu H., Kafonek S. The Lipid Treatment Assessment Project (L-TAP) a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals . Arch Intern Med. 160:2000;459-467.
12. Andrews T.C., Ballantyne C.M., Hsia J.A., Kramer J.H. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med. 111:2001;185-191.
13. Hulley S.B. The US National Cholesterol Education Program. Adult treatment guidelines. Drugs. 36:(suppl 3):1988;100-104.
14. Davidson M.H., Ma P.T.S., Stein E., Gotto A.M. Jr, Raza A., Chitra R., Hutchinson H. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 89:2002;268-275.
15. Data on file, AstraZeneca, Macclesfield, London, UK.
16. Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O, Southworth H, Pears J, Wilpshaar JW. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144:1044-1051.
17. Paoletti R., Fahmy M., Mahla G., Mizan J., Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients a randomised, double-blind study . J Cardiovasc Risk. 8:2001;383-390.
18. Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, Miller E. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002;144:1036-1043.
19. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
20. Peters J.R., Quiter E.S., Brekke M.L., Admire J., Brekke M.J., Mullis R.M., Hunninghake D.B. The Eating Pattern Assessment Tool a simple instrument for assessing dietary fat and cholesterol intake . J Am Diet Assoc. 94:1994;1008-1013.
21. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
22. Nawrocki J.W., Weiss S.R., Davidson M.H., Sprecher D.L., Schwartz S.L., Lupien P.J., Jones P.H., Haber H.E., Black D.M. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 15:1995;678-682.
23. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 81:1998;582-587.
24. Crouse J.R. III, Frohlich J., Ose L., Mercuri M., Tobert J.A. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol. 83:1999;1476-1477.
25. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs D.R. Jr, Bangdiwala S., Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease. Circulation. 79:1989;8-15.